P19P

Overview

P19P is a BCR-ABL PROTAC degrader based on Ponatinib ( HY-12047 ), with a DC 50 value of approximately 20 nM for the wild-type BCR-ABL protein. P19P can effectively degrade various drug-resistant mutants such as T315I, E255K, H396R, and V468F, and exhibits potent anti-proliferative activity in BaF3-BCR-ABL (T315I) cells. P19P maintains strong inhibitory activity against ABL (T315I), with a IC 50 of 13.1 nM. P19P does not inhibit the formation of vascular lumens in HUVEC. P19P can be used for research on chronic myeloid leukemia and acute lymphoblastic leukemia. (Pink: Bcr-Abl ligand ( HY-12047 ); Blue: Cereblon ligand ( HY-14658 ); Black: linker ( HY-180978 )).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Bcr-Abl

Product Information

• Catalog No.: HY-180977
• CAS No.: 2512843-74-0
• Molecular Formula: C55H57F3N12O9
• Molecular Weight: 1087.11
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source